Commercial Due Diligence on a Next Generation Medical Training Tool

Commercial Due Diligence on a Next Generation Medical Training Tool

Christine O'Connell • March 18, 2021
Christine O'Connell • March 18, 2021

Share

Client and project overview

  • Conducted commercial due diligence (CDD) for a leading B2B data and information business.
  • Focused on evaluating the commercial attractiveness of the 3DDA solution market. We also validated the investment thesis – that the target would be a strategic extension for our client’s medical book assets because it capitalized on the growing adoption of digital and virtual reality technologies


Key questions

As part of our CDD process, we focused on the following questions:

  • What was the sub-segment size and notional opportunity for 3DDA tools?
  • Who are the addressable users?
  • What is the range of content and related tools used by students and medical /nursing schools for foundational and advanced anatomy courses?
  • To what extent do current solutions address customer needs?
  • What were the relative strengths and weaknesses of the target and competitors’ capabilities and products across the identified use cases/feature set?
  • What were the synergies between our client the target business?


Methodology highlights

  • Conducted targeted interviews with market experts, current and prospective customers of the target company, competitors’ B2B customers, our client’s B2B customers, and competing vendors
  • Sized the relevant sub-segment using both supply and demand-side methodology
  • Re-built the business plan for both B2B and B2C customers within a tight timeframe with limited access to target management/customer data


Results

Based on our insights, our client acquired the company successfully two months after we delivered the project.

Read More

Will Barden Named Among The Consulting Report’s Top 25 Strategy Leaders of 2025
By Will Barden December 11, 2025
Will Barden, Partner, has been named among "The Consulting Report's" Top 25 Strategy Leaders of 2025. Click here to read more about the award.
Investing in Pharma Technology: A Healthcare Breakfast Discussion
By Rob Larson & Jordan Abrams December 8, 2025
In partnership with Raymond James and Farragut Square Group, Grant Thornton Stax recently hosted a breakfast event to share our investment analysis of the Pharma Technology market.
Miriam El-Baz & Connor Novy Honored as Consulting Magazine Women Leaders
December 2, 2025
Miriam El-Baz and Connor Novy were recognized at the Consulting Magazine Women Leaders awards to highlight the outstanding contributions made by women in consulting. Read more.
Featured in Financier Worldwide—Accelerating value in PE carve-outs: strategy and execution
By Phil Dunne & Peter Rodrigues-Renon November 11, 2025
Financier Worldwide discusses strategy & execution for accelerating value in carve-outs with Phil Dunne and Peter Rodrigues-Renon at Stax, including Gerard Nichol at Grant Thornton. Read more.
Key Considerations for Investors Exploring the Automotive Retail Tech Value Chain
By Sameer Tejani & Max Massaro November 6, 2025
Investment focus in automotive technology continues to broaden beyond OEMs to the core service ecosystem. Read what Sameer Tejani and Max Massaro see in the market.
Grant Thornton Stax Provides Sell-Side Support to SteelEye on its Merger With FundApps​
November 3, 2025
Grant Thornton Stax supported SteelEye, a leading trade and communications surveillance and data analytics platform, on its recent merger with FundApps. Read about the deal here.
Show More